{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:22:54Z","timestamp":1783016574217,"version":"3.54.6"},"reference-count":31,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Objective: The objective of this retrospective cohort is to analyze survival and other outcomes in patients with myasthenia gravis treated with azathioprine in comparison to the standard treatment based on pyridostigmine and corticosteroids. Methods: A retrospective cohort of 90 patients with myasthenia gravis were followed up on for a mean period of 103.8 months. Survival\/mortality was compared between patients receiving azathioprine and those on standard treatment with pyridostigmine and prednisone. Survival analysis was performed with the method of Kaplan\u2013Meier and the Cox proportional hazards model. The long-term side-effects were also reported. Results: The patients on azathioprine had a longer survival according to the unadjusted log-rank test. However, in the multivariate analysis, age at baseline was the only predictor of any cause mortality (HR: 1.12; 95% CI: 1.06\u20131.19), but not the use of azathioprine (HR: 0.30; 95% CI: 0.10\u20131.43). Some malignancies appeared in patients treated for more than 10 years. Hematological abnormalities such as leucopenia, anemia, and pancytopenia occurred in four patients and malignancies in three. Conclusions: The use of azathioprine in MG did not result in longer survival compared to standard treatment. Some hematological alterations and malignancies may appear over time in patients receiving azathioprine.<\/jats:p>","DOI":"10.3390\/jcm14113945","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T11:55:52Z","timestamp":1748951752000},"page":"3945","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-Term Adverse Effects and Survival in Patients with Myasthenia Gravis Treated with Azathioprine: A Retrospective Cohort"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9136-0719","authenticated-orcid":false,"given":"Pedro J.","family":"Modrego","sequence":"first","affiliation":[{"name":"Neurology Department, Miguel Servet University Hospital, 50012 Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/nyas.13522","article-title":"Myasthenia gravis: The role of complement at the neuromuscular junction","volume":"141","author":"Howard","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e631","DOI":"10.1097\/MJT.0000000000001454","article-title":"Pharmacological management of myasthenia gravis: A century of expert opinions in Cecil textbook of Medicine","volume":"28","author":"Manu","year":"2021","journal-title":"Am. J. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3109\/08916930903518107","article-title":"Immunosuppressive therapies in Myasthenia gravis","volume":"43","author":"Sanders","year":"2010","journal-title":"Autoimmunity"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1007\/s13760-023-02242-w","article-title":"Methotrexate in generalized myasthenia gravis: A systematic review","volume":"123","author":"Prado","year":"2023","journal-title":"Acta Neurol. Belg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"20406223221122538","DOI":"10.1177\/20406223221122538","article-title":"Remission and relapses of myasthenia gravis on long-term tacrolimus: A retrospective cross-sectional study of a Chinese cohort","volume":"13","author":"Bi","year":"2022","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/BF00314245","article-title":"Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis","volume":"235","author":"Mantegazza","year":"1988","journal-title":"J. Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia gravis study group","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Myasthenia Gravis Clinical Study Group (1992). A randomized clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. J. Neurol. Neurosurg. Psychiatry, 56, 1157\u20131163.","DOI":"10.1136\/jnnp.56.11.1157"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0022-510X(97)05370-7","article-title":"Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis","volume":"150","author":"Bromberg","year":"1997","journal-title":"J. Neurol. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/j.1468-1331.2009.02634.x","article-title":"Long-term effects of immunosuppressive treatment on myasthenia gravis","volume":"16","author":"Rozsa","year":"2009","journal-title":"Eur. J. Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5819","DOI":"10.1007\/s00415-023-11925-6","article-title":"Mysthenia gravis treatment in the elderly presents with a significant iatrogenic risk: A multicentric retrospective study","volume":"270","author":"Mikor","year":"2023","journal-title":"J. Neurol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jocn.2021.03.015","article-title":"Cancer occurrence following azathioprine treatment in myasthenia gravis patients. A systematic review and meta-analysis","volume":"88","author":"Zhang","year":"2021","journal-title":"J. Clin. Neurosci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/ene.12329","article-title":"Risk of non-melanoma skin cancer in myasthenia gravis treated with azathioprine","volume":"21","author":"Pedersen","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.neurol.2023.09.004","article-title":"Epidemiology of myasthenia gravis in France. A retrospective claim database study (STAMINA)","volume":"180","author":"Laforet","year":"2024","journal-title":"Rev. Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40263-023-01059-8","article-title":"Myasthenia gravis treatment: From old drugs to innovative therapies with a glimpse into the future","volume":"38","author":"Crisafulli","year":"2024","journal-title":"CNS Drugs"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.nmd.2020.08.355","article-title":"Mortality rates and causes of death in Swedish myasthenia gravis patients","volume":"10","author":"Westerberg","year":"2020","journal-title":"Neuromuscul. Disord."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/mus.26132","article-title":"Survival and mortality of adult-onset myasthenia gravis in the population of Belgrade, Serbia","volume":"58","author":"Basta","year":"2018","journal-title":"Muscle Nerve"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/mus.24697","article-title":"Mortality in myasthenia gravis. A nation-wide population-based follow-up study in Denmark","volume":"53","author":"Hansen","year":"2016","journal-title":"Muscle Nerve"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e213505","DOI":"10.1212\/WNL.0000000000213505","article-title":"Demographic and geographic trends in myasthenia gravis-ralated mortality in the United States, 1999\u20132022","volume":"104","author":"Salahat","year":"2025","journal-title":"Neurology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1212\/WNL.38.2.258","article-title":"Azathioprine toxicity during long-term of immunosupression of generalized myasthenia gravis","volume":"38","author":"Hohlfeld","year":"1988","journal-title":"Neurology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/mus.25052","article-title":"Remission and relapse of myasthenia gravis on long-term azathioprine: An ambispective study","volume":"54","author":"Gupta","year":"2016","journal-title":"Muscle Nerve"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e00396","DOI":"10.1002\/brb3.396","article-title":"Non-melanoma skin cancer risk awareness in azathioprine-treated myasthenia gravis patients","volume":"5","author":"McGurgan","year":"2015","journal-title":"Brain Behav."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/ene.14153","article-title":"Serious infections in patients with myasthenia gravis: Population-based cohort study","volume":"27","author":"Kassardjian","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1176636","DOI":"10.3389\/fneur.2023.1176636","article-title":"Therapeutic and prognostic features in myasthenia gravis patients followed in a tertiary neuromuscular diseases center in Turkey","volume":"14","author":"Yaman","year":"2023","journal-title":"Front. Neurol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/cns.13468","article-title":"Immunotherapy choice and maintenance for generalized myasthenagravis in China","volume":"26","author":"Zhang","year":"2020","journal-title":"CNS Neurosci. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1136\/pgmj.66.772.102","article-title":"Long termtreatment of myasthenia gravis with azathioprine","volume":"66","author":"Fonseca","year":"1990","journal-title":"Postgrad. Med. J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1474-4422(24)00028-0","article-title":"Comparative effectiveness of azathioprine and mycophenolate-mofetil for myasthenia gravis (PROMISE-MG): A prospective cohort study","volume":"23","author":"Narayanaswami","year":"2024","journal-title":"Lancet Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e16229","DOI":"10.1111\/ene.16229","article-title":"Generalized myasthenia gravis with acetylcholine receptor antibodies. A guidance for treatment","volume":"31","author":"Gilhus","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","article-title":"Clinical features, pathogenesis, and treatment of myasthenia gravis: A supplement to the guidelines of the German neurological society","volume":"273","author":"Melzer","year":"2016","journal-title":"J. Neurol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/11\/3945\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:46:47Z","timestamp":1760032007000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/11\/3945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["jcm14113945"],"URL":"https:\/\/doi.org\/10.3390\/jcm14113945","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]}}}